6MW5311

N/A

Report date: 2026/04/21 15:28:29

Base Information

Drug Name6MW5311
Drug Alias Name6MW5311
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 4 modulatorsT cell surface glycoprotein CD3 modulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4T cell surface glycoprotein CD3
Therapy Area/IndicationsHematologic NeoplasmsMultiple MyelomaLeukemia, Myelomonocytic, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsMultiple MyelomaLeukemia, Myelomonocytic, Chronic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A